Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02134951 · ClinicalTrials.gov registry record · Phase 4
Biomarker Assessment of Glutamatergic Target Engagement
A Phase 4 study of Healthy (Controls), sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 4
- Development phase
- 65
- Enrollment target
- 3
- Study locations
NCT02134951: Completed Phase 4 study of Healthy (Controls), sponsored by New York State Psychiatric Institute.
NCT02134951 is a Phase 4 study of Healthy (Controls) that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 65 participants, below the 117-participant average among 16 other Healthy (Controls) trials with a reported enrollment target (44% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02134951, a Phase 4 study of Healthy (Controls), has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 65 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this study is to assess the relative feasibility of 2 potential functional measures of target engagement (Glx MRS, BOLD fMRI) to systematically assess mGluR 2/3 in drug development for psychotic spectrum disorders.
Primary Outcome
Compare changes in Glx response to infusion of ketamine vs placebo, as measured by proton magnetic resonance spectroscopy (¹H MRS). Calculated by post-pre changes in the Glx over creatinine ratios, with higher values indicating higher Glx/creatinine ratios.
Conditions Studied
Interventions
- DRUG Ketamine
- DRUG Normal saline
Study Locations (3)
California
- University of California Davis - Sacramento
Connecticut
- Yale University - New Haven
New York
- New York State Psychiatric Institute - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2014-05 |
| Est. Completion | 2015-11 |
| Phase | Phase 4 |
What the finished NCT02134951 record still lists
NCT02134951 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 117-participant average among 16 other Healthy (Controls) trials with a reported enrollment target (44% lower).
The record links to 1 condition, with Healthy (Controls) appearing as the primary indexed condition, and to 2 interventions - of which Ketamine is the first listed.
NCT02134951 reports a single indexed study location in California, Connecticut, New York.
Frequently Asked Questions
What is clinical trial NCT02134951 about?
NCT02134951 is a clinical study titled "Biomarker Assessment of Glutamatergic Target Engagement". The purpose of this study is to assess the relative feasibility of 2 potential functional measures of target engagement (Glx MRS, BOLD fMRI) to systematically assess mGluR 2/3 in drug development for psychotic spectrum disorders.
What is the current status of trial NCT02134951?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 65 participants. The study started on 2014-05. Estimated completion is 2015-11.
What conditions does trial NCT02134951 study?
This clinical trial studies the following conditions: Healthy (Controls).
What interventions are being tested in trial NCT02134951?
The interventions under investigation include: Ketamine (DRUG), Normal saline (DRUG).
Who is sponsoring clinical trial NCT02134951?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02134951 being conducted?
This trial has 3 study locations across California, Connecticut, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy (Controls)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02134951's enrollment target sits among peer trials
65 11th of 16 higher than 6 of 16 other Healthy (Controls) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy (Controls) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Elucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia
RECRUITING · Phase 4
-
Cold and Heat Investigation to Lower Levels of Depression
RECRUITING · NA
-
Ultralow Dose PET Imaging of SSTR2 Radiotracer Uptake
RECRUITING · Phase 2
-
Decoding Emotional Dynamics in Bipolar Disorder
RECRUITING · NA
-
Subthreshold Vestibular Stimulation as a Strategy for Rehabilitation
RECRUITING · NA
-
PET Imaging Evaluation of [11C]SY08
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia